23 August 2019 - Medipost said that the U.S. FDA has given a fast- track designation for Pneumostem, a bronchopulmonary dysplasia treatment for preterm infants.
The fast-track designation comes after the FDA gave an orphan drug designation for the drug in 2014.
The company has also completed phase 1 and 2 clinical trials in the U.S. in January this year.